Rising prices and damaging change charges are affecting the dialysis supplier’s earnings Fresenius Medical Care (FMC) dampened. The working consequence adjusted for particular results climbed by 2 % to 467 million euros within the first quarter, because the DAX group introduced on Tuesday in Unhealthy Homburg. With out foreign money results, the rise would have been ten % in comparison with the earlier yr.
The underside line is that the blood washing specialist needed to settle for vital losses: Group earnings fell by 22 % to 118 million euros. Income fell by 6 % to 4.6 billion euros, however at fixed change charges the rise was 3 %.
CEO Helen Giza confirmed the enterprise forecasts. The supervisor has declared 2026 to be a transition yr after FMC had made a giant leap in earnings in 2025. The reason being, amongst different issues, prices for the present introduction of a contemporary dialysis machine within the USA, which Giza sees as an funding in a greater future. On the identical time, FMC is pushing forward with its cost-cutting measures and the discount of its clinic community. On the finish of March, the group had virtually 290,000 sufferers who have been handled in 3,539 dialysis clinics worldwide.
© dpa-infocom, dpa:260505-930-34978/1